NASDAQ:ACAD
ACADIA Pharmaceuticals Inc. Stock News
$16.59
-0.150 (-0.90%)
At Close: Apr 24, 2024
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
08:06pm, Thursday, 07'th May 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous syste
ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
08:05pm, Thursday, 07'th May 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Vanderbilt University today announced an exclusive worldwide license agreement to develop and commercialize novel drug candidates targeting the muscarini
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
08:05pm, Tuesday, 05'th May 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the following two investor conferences:
Start-up gets $1 billion valuation virtually, as coronavirus shifts Silicon Valley hunt for IPO riches
01:54pm, Tuesday, 05'th May 2020
When VAST Data became a unicorn, valued at over $1 billion, in April, it relied on virtual meetings with investors, as Silicon Valley VCs and the IPO market navigate Covid-19.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
12:00am, Tuesday, 05'th May 2020Acadia Pharmaceuticals: Targeting A Strong Return By Year End
08:12pm, Monday, 04'th May 2020
After a huge rally in April, stocks finally saw some significant profit taking last week, leaving some good stocks with lower entry levels. This includes Acadia
3 Promising Biotech Stocks to Buy on a Market Pullback
02:00pm, Monday, 04'th May 2020
Eagle Pharmaceuticals, Biohaven Pharmaceuticals and Acadia Pharmaceuticals are names to consider on a 10% move down in equities.
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Down 7% Following Insider Selling
06:00am, Saturday, 02'nd May 2020
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s stock price traded down 7% on Friday following insider selling activity. The stock traded as low as $44.22 and last traded at $44.93, 1,186,651 shares cha
Viking Therapeutics (VKTX) Received its Third Buy in a Row
07:58pm, Friday, 01'st May 2020
After William Blair and Stifel Nicolaus gave Viking Therapeutics (NASDAQ: VKTX) a Buy rating last month, the company received another Buy, this time from
Viking Therapeutics (VKTX) Received its Third Buy in a Row
07:58pm, Friday, 01'st May 2020
After William Blair and Stifel Nicolaus gave Viking Therapeutics (NASDAQ: VKTX) a Buy rating last month, the company received another
ACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded by BidaskClub to Hold
07:38am, Friday, 01'st May 2020
ACADIA Pharmaceuticals (NASDAQ:ACAD) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday,
Oppenheimer Believes Amgen (AMGN) Won't Stop Here
04:17am, Friday, 01'st May 2020
Oppenheimer analyst Jay Olson assigned a Buy rating to Amgen (AMGN) today and set a price target of $252.00. The company's shares closed last Thursday at
Oppenheimer Believes Amgen (NASDAQ: AMGN) Won’t Stop Here
04:17am, Friday, 01'st May 2020
Oppenheimer analyst Jay Olson assigned a Buy rating to Amgen (AMGN – Research Report) today and set a price target
